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How Presenilin mutations cause
Alzheimer’s disease is a key unresolved
problem. Xia et al. show, unexpectedly,
that such mutations cause AD-like
symptoms in mice through a loss-of-
function mechanism, suggesting that
restoring Presenilin function may be a
promising therapeutic strategy.
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Presenilins play essential roles in memory formation,
synaptic function, and neuronal survival. Mutations
in the Presenilin-1 (PSEN1) gene are the major cause
of familial Alzheimer’s disease (FAD). How PSEN1
mutations cause FAD is unclear, and pathogenic
mechanisms based on gain or loss of function have
been proposed. Here, we generated Psen1 knockin
(KI) mice carrying the FAD mutation L435F or
C410Y. Remarkably, KI mice homozygous for either
mutation recapitulate the phenotypes of Psen1/
mice. Neither mutation altered Psen1mRNA expres-
sion, but both abolished g-secretase activity. Het-
erozygosity for the KI mutation decreased produc-
tion of Ab40 and Ab42, increased the Ab42/Ab40
ratio, and exacerbated Ab deposition. Furthermore,
the L435F mutation impairs hippocampal synaptic
plasticity and memory and causes age-dependent
neurodegeneration in the aging cerebral cortex.
Collectively, our findings reveal that FAD mutations
can cause complete loss of Presenilin-1 function
in vivo, suggesting that clinical PSENmutations pro-
duce FAD through a loss-of-function mechanism.
INTRODUCTION
Dominant mutations in the PSEN1 and PSEN2 genes encoding
Presenilin-1 (PS1) and Presenilin-2 (PS2) are the major cause
of familial Alzheimer’s disease, and more than 200 distinct caus-
ative mutations distributed throughout the coding sequences
have been identified (http://www.alzforum.org/mutations). Pre-
senilin (PS) comprises the catalytic component of g-secretase
(Li et al., 2000), which carries out intramembranous cleavage
of type I transmembrane proteins, including the amyloid pre-
cursor protein (APP) and Notch receptors (De Strooper et al.,
1999; Song et al., 1999; Struhl and Greenwald, 1999). Psen1
null mice display perinatal lethality with developmental defectsand impaired neurogenesis attributable to loss of Notch
signaling activity (Handler et al., 2000; Shen et al., 1997),
whereas Psen2 null mice have no detectable brain phenotypes
(Saura et al., 2004; Steiner et al., 1999). In the adult brain, Prese-
nilins play essential roles in synaptic function, learning andmem-
ory, and neuronal survival (Saura et al., 2004; Wines-Samuelson
et al., 2010; Yu et al., 2001; Zhang et al., 2009, 2010).
Despite these insights into PS function in the brain, the mech-
anism by which PSENmutations lead to neurodegeneration and
dementia in FAD remains a key unresolved issue. Both gain-of-
function (Hardy and Selkoe, 2002) and loss-of-function (Shen
and Kelleher, 2007) pathogenic mechanisms have been pro-
posed. FAD mutations in PSEN have been reported to increase
Ab42 production selectively, suggesting that PSEN mutations
may cause FAD via increased Ab42/Ab40 ratio (Borchelt et al.,
1996; Duff et al., 1996; Scheuner et al., 1996). However, FAD pa-
tients carrying PSEN mutations develop the disease at a signifi-
cantly earlier age of onset, relative to APP mutations (Ryman
et al., 2014), even though the increase in the Ab42/Ab40 ratio
conferred by PSEN mutations is typically rather small. Further-
more, overproduction of Ab including Ab42 has failed to produce
significant neurodegeneration in mice (Games et al., 1995; Hsiao
et al., 1996; Mucke et al., 2000), suggesting that Ab42 overpro-
duction itself may be insufficient to initiate neurodegeneration.
Surprisingly, conditional inactivation of Presenilins (Beglopoulos
et al., 2004; Saura et al., 2004; Wines-Samuelson et al., 2010) or
another component of the g-secretase complex Nicastrin (Tab-
uchi et al., 2009) in the adult mouse brain produced widespread
neurodegeneration, inflammation, and tau hyperphosphoryla-
tion, raising the possibility that PSENmutations may cause neu-
rodegeneration and dementia in FAD via a loss of essential PS
functions.
Using a sensitive cell-based assay system, we found that a se-
ries of clinical PSEN1 mutations uniformly impaired g-secretase
activity with the L435F and C410Y mutations causing virtually
complete loss of g-secretase-dependent processing of APP
and Notch (Heilig et al., 2010, 2013). These findings raised the
pivotal question of whether FAD mutations cause a loss of PS
function in vivo, and whether loss of PS function by clinical mu-
tations can trigger key AD-related phenotypes. To address these
questions, we introduced the L435F or C410Y mutation into theNeuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc. 967
genomic Psen1 locus and analyzed their impact on PS1 function
and g-secretase activity in the developing and adult brain. Strik-
ingly, both the L435F and C410Y mutations yielded null alleles
in vivo, as knockin (KI) mice homozygous for either mutation dis-
played morphological, neurodevelopmental, and biochemical
phenotypes indistinguishable from those of Psen1 null mice.
Moreover, replacement of a wild-type Psen1 allele with the
L435F KI allele in adult mice produced a series of neuropatholog-
ical, synaptic, and behavioral changes relevant to FAD, including
elevation of the Ab42/Ab40 ratio and accelerated Ab deposition
in a human APP transgenic background, impaired hippocampal
synaptic plasticity and memory, and cerebral cortical neurode-
generation. Collectively, these findings support the hypothesis
that loss of PS essential functions plays an important role in
FAD pathogenesis.
RESULTS
FAD Mutations L435F and C410Y Preserve Psen1
mRNA Expression but Reproduce Psen1 Null
Phenotypes In Vivo
To determine the impact of FAD mutations in vivo, we generated
two independent KI mice in which the FAD-linked L435F or
C410Y mutation was introduced into the genomic Psen1 locus.
The L435F mutation was identified in early-onset FAD with cere-
bral cotton wool plaque neuropathology (Heilig et al., 2010; Ro-
gaeva et al., 2001). The C410Y substitution was one of the first
five FAD mutations reported in PSEN1 (Sherrington et al.,
1995) and has been extensively characterized, including its as-
sociation with cerebral cotton wool plaques (Haleem et al.,
2007; Klunk et al., 2007; Moonis et al., 2005). The L435F or
C410Y missense mutation was introduced into Psen1 exon 12
or 11, respectively, by homologous recombination (Figure 1A)
and further verified by Southern analysis and sequencing (Fig-
ures S1A–S1C).
Strikingly, homozygous Psen1L435F/L435F (L435F KI/KI) and
Psen1C410Y/C410Y (C410Y KI/KI) mice display developmental ab-
normalities indistinguishable from the phenotypes observed in
Psen1/ mice (Shen et al., 1997), including perinatal lethality,
shortened rostro-caudal body axis, and shortened, kinked tails
(Figure 1B; Table S1). To determine whether introduction of the
FAD mutation disrupts Psen1 expression, we examined Psen1
mRNA levels in L435F and C410Y KI/KI, KI/+, and Psen1+/+
brains at postnatal day 0 (P0). In contrast to the absence of
Psen1mRNA in Psen1/mice (Shen et al., 1997), northern anal-
ysis showed normal levels of full-length Psen1 mRNA in KI/KI
brains (Figure 1C). Western analysis revealed drastically reduced
levels of endoproteolytically processed PS1 N- and C-terminal
fragments (NTFs and CTFs) in KI/KI brains and corresponding
accumulation of PS1 holoprotein in a KI allele dosage-depen-
dent manner (Figure 1D). Thus, the L435F and C410Y mutations
do not affect Psen1 mRNA expression but abolish the normal
presenilinase activity of PS1. To assess whether the L435F mu-
tation affects the expression of g-secretase complex compo-
nents, we measured levels of Nicastrin and Pen-2 and found
that they are similar in Psen1+/+, L435F KI/KI, and KI/+ brains
but significantly reduced in Psen1/ brains (Figure S1D), sug-
gesting that PS1 holoprotein with the L435Fmutation is sufficient968 Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc.to maintain normal levels of other g-secretase components,
despite the drastic reduction of PS1 NTFs and CTFs.
Impaired Notch Signaling and Neurogenesis in L435F
and C410Y KI/KI Mice
Presenilin is required for the proteolytic cleavage of Notch to
release its intracellular effector domain (NICD) (Struhl andGreen-
wald, 1999). We assessed Notch signaling activity using an
in vitro assay for de novo NICD production and found that
NICD production is markedly reduced in L435F and C410Y
KI/+ brains and largely eliminated in KI/KI brains (Figure 2A).
Northern analysis revealed that levels of the Notch effector
gene Hes5 are decreased in L435F and C410Y KI/KI brains to
a similar extent as those in Psen1/ brains (Figure 2B). These
data provide further confirmation that the L435F and C410Y KI
mutations impair Notch signaling.
Inactivation of PS1 function causes neural developmental de-
fects, including depletion of neural progenitor cells and impaired
neurogenesis (Handler et al., 2000; Kim and Shen, 2008; Shen
et al., 1997). We therefore evaluated the impact of the L435F
and C410Ymutations on brain development. Similar to Psen1/
mice (Handler et al., 2000; Shen et al., 1997), L435F and C410Y
KI/KI mice display pronounced thinning of the ventricular zones
within the lateral ganglionic eminence and developing telen-
cephalon at embryonic day 16.5 (E16.5) compared to littermate
Psen1+/+ mice (Figure 2C). Moreover, the number of proliferating
cells detected by Ki67 immunoreactivity is significantly reduced
in the ventricular zone of L435F and C410Y KI/KI brains (Fig-
ure 2D). These phenotypes bear striking resemblance to those
inPsen1/mice (Shen et al., 1997), further indicating that the ef-
fects of the L435F and C410Y mutations on neurodevelopment
and g-secretase-mediated cleavage of Notch are comparable
to the null mutation.
Inactivation of g-Secretase by the L435F
and C410Y Mutations
To investigate further the impact of the L435F and C410Y muta-
tions on g-secretase activity, we examined proteolytic process-
ing of APP. Western analysis revealed that APP CTFs, the direct
substrate of g-secretase, accumulate to a similar extent in L435F
and C410Y KI/KI mice and Psen1/ mice, indicating compara-
ble deficiencies in g-secretase activity (Figure 3A; Figure S2A).
We next analyzed g-secretase activity using an in vitro assay
for de novo Ab production (Takahashi et al., 2003; Watanabe
et al., 2012) and found that production of Ab40 and Ab42 is ab-
sent in KI/KI brains and markedly reduced in KI/+ brains for
each mutation (Figure 3B; Figure S2B). We also measured the
steady-state levels of endogenous mouse Ab directly from brain
homogenates. Strikingly, endogenous Ab40 and Ab42 are unde-
tectable in KI/KI brains, whereas Ab40 and Ab42 levels in KI/+
embryonic brains are similar to those in Psen1+/+ brains for
each mutation (Figure 3C; Figure S2C). N-Cadherin CTF1,
another g-secretase substrate (Marambaud et al., 2003), also
displayed significant accumulation in L435F and C410Y KI/KI
as well as Psen1/ brains (Figure S2D). These results demon-
strate that the L435F and C410Y mutations disrupt g-secretase
activity to an extent comparable to complete loss of PS1
function.
Figure 1. L435F and C410Y KI/KI Mice Exhibit Phenotypes Indistinguishable from Psen1–/– Mice
(A) Targeting strategy for the generation of L435F and C410Y KI mice. Boxes represent Psen1 exons 8–12, and the locations of the 50 and 30 external probes are
shown. The L435F mutation is located in exon 12, and C410Y mutation is located in exon 11. Ba and Ap denote BamHI and ApaI restriction sites, respectively.
(B) Newborn L435F and C410Y KI/KI pups resemble Psen1/ pups with shortened tail and rostrocaudal body axis.
(C) Northern analysis of brain total RNA at P0 shows normal Psen1 mRNA size and level in L435F and C410Y KI/KI and KI/+ mice (nR 5).
(D) Western analysis of brain lysates at P0 shows residual amounts of PS1 NTFs and CTFs in L435F and C410Y KI/KI brains and drastic accumulation of PS1
holoprotein in L435F and C410Y KI/KI and KI/+ brains in a KI gene dosage-dependent manner, whereas these PS1 species are undetectable in Psen1/ brains
(nR 4). Data are represented as mean ± SEM. ***p < 0.001.
See also Figure S1 and Table S1.
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Figure 2. Impaired Neurogenesis and Notch
Signaling in L435F and C410Y KI/KI Mice
(A) In vitro g-secretase assay using CHAPSO-solubi-
lized E18.5 brain fractions and recombinant Notch
substrate N102-FmH followed by western analysis
reveals that NICD production is reduced in L435F KI/+
(n = 3) and C410Y KI/+ (n = 4) mice and abolished in
L435F KI/KI (n = 3) and C410Y KI/KI (n = 3) mice
compared to Psen1+/+ controls (n = 6). SNAP25 is
used as internal loading control for membrane frac-
tions.
(B) Northern analysis of Hes5 expression. Levels of
Hes5 mRNA are markedly reduced in L435F KI/KI
(n = 9), C410Y KI/KI (n = 3), Psen1/ (n = 3) brains
relative to Psen1+/+ controls (n = 7).
(C) H&E staining of comparable brain sections from
L435F KI/KI, C410Y KI/KI, and littermate controls at
E16.5 shows that the ventricular zone (VZ) and the
developing cortical plate (CP) are thinner in L435F KI/
KI and C410Y KI/KI mice. The bottom panels show
higher-power views of the boxed areas in the devel-
oping CP. Dashed lines show the boundaries of the
CP. Scale bar, 0.25 mm.
(D) The number of proliferating neural progenitor cells
in the VZ labeled by Ki67 immunoreactivity is reduced
in L435F KI/KI and C410Y KI/KI brains at E16.5 (n = 4
for each genotype). Scale bar, 0.25 mm. Data are
represented as mean ± SEM. ***p < 0.001.
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Figure 3. Abolished Ab Production in L435F KI/KI Mice and Reduced Ab40 and Ab42 Production in L435F KI/+ Mice
(A) APP CTFs accumulate (>10-fold) in L435F KI/KI and Psen1/ brains relative to littermate controls at E18.5 (nR 6).
(B) ELISA measurements of Ab40 and Ab42 following in vitro g-secretase assay. In vitro g-secretase assay reveals that de novo generation of Ab40 and Ab42 in
L435F KI/+ brains at E18.5 (n = 4) is reduced by 46% and 43%, respectively, compared to Psen1+/+ brains (n = 5), and they are undetectable in L435F KI/KI brains
(n = 3).
(C) ELISAmeasurements of endogenous Ab40 and Ab42 from brain homogenates at E18.5. Levels of stead-state endogenous Ab40 and Ab42 are similar between
L435F KI/+ and Psen1+/+ brains, and they are undetectable in L435F KI/KI brains (n = 4 for each genotype).
(D) ELISAmeasurements of Ab40 and Ab42 following in vitro g-secretase assay in 3-month-old mice. De novo generation of Ab40 and Ab42 in L435F KI/+ cortical
homogenates is reduced by 47% and 43%, respectively, compared to Psen1+/+ cortices (n = 6 for each genotype).
(E) ELISAmeasurements of steady-state endogenous Ab40 and Ab42 in both insoluble and soluble fractions from cortical samples at 3months of age. In insoluble
fractions, levels of endogenous Ab40 and Ab42 are reduced in L435F KI/+ cortices (n = 10) relative to controls (n = 7), and the Ab42/Ab40 ratio is increased. In
soluble fractions, levels of endogenous Ab40 and Ab42 are not significantly different between Psen1L435F/+ and Psen1+/+ cortices, but the Ab42/Ab40 ratio is
significantly increased in Psen1L435F/+ cortices. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S2 and Table S2.Reduction of Ab40andAb42Production andElevation of
the Ab42/Ab40 Ratio in Adult KI/+ Brains
Although L435F KI/KI mice exhibit perinatal lethality, L435F KI/+
mice are viable and fertile. Notably, L435F KI/+ mice provide a
precise genetic animal model of the PSEN1 mutation in FAD.
To determine how the L435F mutation affects Ab production in
the adult brain, we performed in vitro assay using L435F KI/+
and littermate Psen1+/+ mice at 3 months of age. Levels of de
novo Ab40 and Ab42 production in L435F KI/+ mice are reduced
to approximately half of those in Psen1+/+ mice (Figure 3D). We
next measured steady-state levels of endogenous Ab40 and
Ab42 in both insoluble and soluble fractions from the cerebral
cortex at 3 months of age. In insoluble fractions, levels of Ab40
and Ab42 are significantly reduced (by 29% and 17%, respec-
tively), and the Ab42/Ab40 ratio is correspondingly increased
(15%) in L435FKI/+mice (Figure 3E). In soluble fractions, levels
of Ab40 and Ab42 are lower than those in insoluble fractions and
not significantly altered, but the ratio of Ab42/Ab40 is elevated inL435F KI/+ mice compared to that in Psen1+/+ mice (Figure 3E).
These results show that heterozygosity for the L435F mutation
elevates the Ab42/Ab40 ratio due to a greater reduction in accu-
mulation of Ab40 relative to Ab42.
The L435F KI Mutation Exacerbates Ab Plaque
Deposition in Human Mutant APP Transgenic Mice
To investigate how the loss of PS1 function conferred by the
L435F mutation affects human Ab production and plaque forma-
tion, we crossed L435F KI/+ mice to transgenic mice overex-
pressing human wild-type (APPWT, I5 line) or mutant (APPMT,
J20 line) APP (Mucke et al., 2000) in which Ab40 and Ab42 are
dramatically overproduced (Table S2). We first measured levels
of human Ab40 and Ab42 in insoluble and soluble fractions
from the cerebral cortex of Psen1L435F/+; APPWT and Psen1+/+;
APPWT mice at 9 months of age (Figure 4A). In Psen1L435F/+;
APPWT mice, steady-state levels of human Ab40 and Ab42 are
significantly reduced in insoluble fractions, and the Ab42/Ab40Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc. 971
Figure 4. Reduced Human Ab Accumulation, but Accelerated Amyloid Deposition in L435F KI/+ Mice Expressing a Human Mutant APP
Transgene
(A) ELISAmeasurements of steady-state human Ab40 and Ab42 in insoluble and soluble fractions fromPsen1L435F/+; APPWT (n = 4) and controls (n = 4) at 9months
of age. In Psen1L435F/+; APPWTmice, human Ab40 is reduced by26% in insoluble fractions and62% in soluble fractions, whereas human Ab42 is reduced by
19% in insoluble fractions, but is not significantly changed in soluble fractions. Note that levels of Ab40 and Ab42 are much higher in insoluble fractions than in
soluble fractions (>20-fold for Ab40, >10-fold for Ab42). The Ab42/Ab40 ratio is significantly enhanced in soluble and insoluble fractions.
(B) ELISA measurements of steady-state human Ab40 and Ab42 in insoluble and soluble fractions of cortical homogenates from Psen1+/+; APPMT (n = 4) and
Psen1L435F/+; APPMT (n = 4) at 2months of age. Levels of human Ab40 are significantly reduced in insoluble fractions, but not in soluble fractions, whereas levels of
human Ab42 are not significantly altered. Note that levels of Ab40 are drastically higher in insoluble fractions than in soluble fractions (>100-fold). The Ab42/Ab40
ratio is significantly increased in insoluble fractions.
(C) Ab immunostaining with an Ab antibody (R1282) reveals significantly increased plaque deposition in the cerebral cortex of Psen1L435F/+; APPMT mice
compared to Psen1+/+; APPMT mice at 9 months of age. Scale bar, 0.25 mm. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3 and Table S2.ratio is increased; in soluble fractions, levels of human Ab40 are
markedly reduced, and the Ab42/Ab40 ratio is increased,
although levels of Ab42 are not significantly changed (Figure 4A).
No amyloid plaque deposition was detected in the cerebral
cortex ofPsen1L435F/+; APPWTmice even at the age of 18months
(Figure S3).972 Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc.Similarly, we measured levels of human Ab40 and Ab42 in
insoluble and soluble fractions from the cerebral cortex of
Psen1L435F/+; APPMT and Psen1+/+; APPMT mice at 2 months of
age (Figure 4B). InPsen1L435F/+; APPMTmice, steady-state levels
of human Ab40 are significantly reduced in insoluble fractions,
and the Ab42/Ab40 ratio is increased (Figure 4B). Furthermore,
Figure 5. Memory Impairment Caused by the L435F Mutation
(A)Psen1L435F/+;Psen2/ (KI/+;/) mice (n = 14) showed significantly higher escape latencies thanPsen1+/+;Psen2/ (+/+;/) littermates (n = 15) during the
14-day training period (F1, 27 = 8.06; p < 0.01) in the Morris water maze test.
(B) Psen1L435F/+; Psen2/ mice show significantly reduced target quadrant occupancy in the day 7 probe test, but both genotypic groups show similar target
quadrant occupancy in the day 13 probe test. Psen1L435F/+; Psen2/ mice display significantly reduced quadrant occupancy in the partial-cue probe test on
day 14. T, target quadrant; AL, adjacent left quadrant; AR, adjacent right quadrant; OP, opposite quadrant.
(C) Naive Psen1L435F/+;Psen2/mice (n = 10) and littermate controls (n = 9) were subjected to 8 days of training to locate the three baited arms (indicated by red *)
following fasting in the radial arm maze test.
(D) Psen1L435F/+; Psen2/ and control mice require similar amounts of time to complete the food search (F1, 17 = 1.18, p > 0.05) during the 8-day radial armmaze
training.
(E) Psen1L435F/+; Psen2/ mice display significantly more reference errors (F1, 17 = 4.59, p < 0.05) during the 8-day training period.
(F)Psen1L435F/+;Psen2/mice show significantly higher percentages of 45 turns (F1, 17 = 13.63, p < 0.001) during the 8-day training period. Data are represented
as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.Ab immunostaining disclosed accelerated amyloid deposition in
the cerebral cortex of Psen1L435F/+; APPMT mice compared to
Psen1+/+; APPMT mice at 9 months of age (Figure 4C). Thus,
although the L435F mutation abolishes the g-secretase activity
of mutant PS1 protein, heterozygosity for the mutation neverthe-
less enhances the Ab42/Ab40 ratio and promotes amyloid
deposition.
Memory Impairment Caused by the L435F Mutation
To determine the impact of the L435F mutation on hippocampal
learning and memory, we assessed the performance of
Psen1L435F/+; Psen2/ (KI/+;/) mice and Psen1+/+; Psen2/
(+/+; /) control littermates using the Morris water maze and
radial arm maze tasks. Previous work has shown that PS2
expression is upregulated in the absence of PS1 (Watanabe
et al., 2014), which may compensate for behavioral and synaptic
deficits caused by PS1 deficiency. We therefore examined the
impact of the L435Fmutation on behavioral and synaptic pheno-
types in a Psen2/ background. We first analyzed hippocampalreference memory in the hidden-platform Morris water maze
task. Psen1L435F/+; Psen2/ mice exhibited significantly higher
latencies across the 14-day training period (p < 0.01, Figure 5A)
and displayed significantly lower target quadrant occupancy in
the probe test at day 7 (p < 0.01, Figure 5B), indicating impaired
reference memory acquisition. Both genotypic groups showed
similar target quadrant occupancies in the probe trial at day 13
(Figure 5B), suggesting that additional training overcame this
reference memory deficit.
The hippocampus mediates pattern completion during mem-
ory recall, an ability to retrieve stored memory traces in response
to incomplete sensory cues (Nakazawa et al., 2002). Neuropsy-
chological analysis has shown evidence for impaired behavioral
pattern completion in AD patients (Ally et al., 2013). To assess
pattern completion, we removed three of the four distal spatial
cues and administered another probe trial at day 14. Despite
their normal quadrant occupancy under full-cue conditions on
day 13, Psen1L435F/+; Psen2/ mice displayed reduced target
quadrant occupancy under partial-cue conditions (p < 0.05,Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc. 973
Figure 5B), suggesting impaired hippocampal pattern comple-
tion. Psen1L435F/+; Psen2/ mice exhibited normal escape la-
tency, path length, and swim speed in the visible platform water
maze task (Figure S4), indicating that the observed learning and
memory impairments are not attributable to deficits in vision,
motivation, or sensorimotor abilities.
To obtain an independent assessment of hippocampal mem-
ory, we further subjected naive Psen1L435F/+; Psen2/ and litter-
mate control mice to a spatial discrimination version of the radial
arm maze task (Dillon et al., 2008; Rossi-Arnaud et al., 1991).
Psen1L435F/+; Psen2/ and their littermate controls were trained
to locate three baited arms over 8 consecutive days (Figure 5C).
Although both genotypic groups required similar amounts of time
to complete the task (Figure 5D), Psen1L435F/+; Psen2/ mice
showed more reference memory errors (p < 0.05, Figure 5E)
and a higher proportion of 45 turns into adjacent arms (p <
0.001, Figure 5F). Thus, multiple behavioral tasks revealed hippo-
campal spatial memory deficits caused by the L435F KImutation.
Synaptic Dysfunction Caused by the L435F Mutation
We then performed electrophysiological analysis onPsen1L435F/+;
Psen2/ mice and Psen1+/+; Psen2/ littermate controls to
determine the effect of the L435F mutation on hippocampal
synaptic function and to investigate the cellular mechanism un-
derlying the identified memory defects. Whereas basal synaptic
transmission was normal in the Schaffer collateral pathway (Fig-
ure 6A), Psen1L435F/+; Psen2/ mice displayed impaired short-
term plasticity, as indicated by reduced paired-pulse facilitation
(Figure 6B) and frequency facilitation (Figure 6C). As the im-
pairment in frequency facilitation was already maximal at the
5-Hz stimulation frequency, we tested whether the observed
deficits in short-term synaptic plasticity at this frequency of
presynaptic activation could affect the inducibility of long-term
potentiation (LTP) at the Schaffer collateral-CA1 synapses.
Using voltage-clamp recording, we found that LTP induced by
pairing presynaptic stimuli with postsynaptic depolarization was
significantly reduced in Psen1L435F/+; Psen2/ mice compared
to littermate controls (Figure 6D), whereas NMDAR-mediated
EPSCswere unaffected (Figure S5). These impairments resemble
the synaptic phenotypes previously identified in mice with condi-
tional Psen1/2 inactivation (Saura et al., 2004; Zhang et al., 2009,
2010).
We further assessed synaptic plasticity at commissural/asso-
ciational (C/A)-CA3 synapses, as pattern completion is thought
to be mediated by the recurrent collateral connectivity of CA3
neurons (Nakazawa et al., 2002). We found that LTP was
impaired at (C/A)-CA3 synapses in Psen1L435F/+; Psen2/
mice (Figure 6E). Moreover, short-term depression during the
initial phase of the LTP-inducing stimulus train was increased
at (C/A)-CA3 synapses of Psen1L435F/+; Psen2/ mice (Fig-
ure 6F). These data indicate that the L435F mutation impairs
short-term and long-term synaptic plasticity at hippocampal
CA1 and CA3 synapses.
The L435F Mutation Causes Age-Dependent
Neurodegeneration
Conditional inactivation of PS in the adult cerebral cortex using
the Camk2a-Cre transgene causes severe, age-dependent neu-974 Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc.rodegeneration (Saura et al., 2004; Wines-Samuelson et al.,
2010). Further analysis of Psen conditional knockout mice with
varying Psen2 gene dosage showed that partial inactivation of
PS also results in age-dependent neurodegeneration, though
with lesser severity and a later age of onset (Watanabe et al.,
2014). To examine the impact of the L435F mutation on neuronal
survival, relative to the Psen1 wild-type allele, we generated
Psen1F/L435F; Psen2/; Camk2a-Cre mice and littermate
Psen1F/+; Psen2/; Camk2a-Cre and Psen1F/F; Psen2/
mice. Remarkably, Psen1F/L435F; Psen2/; Camk2a-Cre mice
display age-dependent neurodegeneration throughout the cere-
bral cortex, with marked reductions in cortical volume (31.5% ±
5.2%) and neuron number (22.1% ± 1.4%) at 18 months of age
(Figure 7A), whereas Psen1F/+; Psen2/; Camk2a-Cre mice,
which have one wild-type Psen1 allele, show no neurodegener-
ation (Figure 7A). Moreover, increased apoptosis was identified
by TUNEL staining (Figure 7B) and cleaved caspase-3 immuno-
staining (Figure 7C) in the neocortex of Psen1F/L435F; Psen2/;
Camk2a-Cre mice.
We further evaluated astrogliosis and microgliosis, as inflam-
matory responses often accompany neurodegeneration. Immu-
nohistochemical and western analyses reveal enhanced GFAP
levels in the cortex of Psen1F/L435F; Psen2/; Camk2a-Cre
mice (Figure 7D), indicating the occurrence of astrogliosis in
these mice. We also found that immunoreactivity for the micro-
glial marker Iba1 is elevated in the neocortex and hippocampus
of Psen1F/L435F; Psen2/; Camk2a-Cre mice (Figure S6), indi-
cating that neurodegeneration is also associated with microglio-
sis. These data demonstrate that the L435F mutation abolishes
the ability of PS1 to support neuronal survival during aging.
DISCUSSION
Large numbers of PSEN mutations are linked to FAD, but how
these mutations cause the disease remains unresolved. Earlier
studies in patient plasma, transgenic mice, and cell lines found
that PSEN mutations increased Ab42 levels and/or the Ab42/
Ab40 ratio (Borchelt et al., 1996; Duff et al., 1996; Hardy and Sel-
koe, 2002; Scheuner et al., 1996), leading to the hypothesis that
PSEN mutations cause FAD via a gain-of-function mechanism
mediated by selective overproduction of Ab42 (Hardy and Sel-
koe, 2002). Interestingly, genetic rescue studies in C. elegans
showed that PSENmutations resulted in partial loss of PS activ-
ity (Levitan et al., 1996). However, overexpression of the Psen1
A246E transgene rescued the phenotypes of Psen1/ mice
(Davis et al., 1998; Qian et al., 1998), and KI mice carrying the
Psen1 M146V mutation did not exhibit phenotypes of Psen1/
mice (Guo et al., 1999), though they exhibited hippocampal
memory deficits (Sun et al., 2005). These findings suggested
that PSEN mutations might not impair PS function in the
mammalian brain.
Subsequent genetic studies yielded the surprising discovery
that loss of PS function in the adult cerebral cortex recapitulates
key features of AD, including progressive memory deficits and
age-dependent, widespread neurodegeneration (Beglopoulos
et al., 2004; Saura et al., 2004; Wines-Samuelson et al., 2010).
Furthermore, similar genetic analysis of another g-secretase
component, Nicastrin, confirmed the importance of g-secretase
Figure 6. Synaptic Dysfunction Caused by the L435F Mutation
(A) Normal basal synaptic transmission in Psen1L435F/+; Psen2/mice. The synaptic input-output relationship was obtained by plotting the fiber volley amplitude
against the initial slope of the evoked fEPSP. Each point represents data averaged across all slices for a narrow bin of FV amplitude. The lines represent the best
linear regression fit.
(B) Reduced paired-pulse facilitation (PPF) in Psen1L435F/+; Psen2/mice. The graph depicts the paired-pulse response ratio obtained at different inter-stimulus
intervals (in ms). Scale bar, 1 mV, 50 ms.
(C) Synaptic facilitation elicited by stimulus trains of the indicated frequencies in Psen1L435F/+; Psen2/ and littermate control mice. Frequency facilitation is
significantly decreased in the 5–20 Hz range in Psen1L435F/+; Psen2/ mice. Scale bar, 1 Hz: 1 mV, 500 ms; 20 Hz: 1 mV, 50 ms. FP, field potential.
(D) Pairing-induced LTP at the Schaffer collateral-CA1 synapses in slices from Psen1L435F/+; Psen2/mice and littermate controls. Representative traces before
(thin) and after (thick) LTP induction are shown. Insets show the average of 15 EPSCs recorded before and 45–50 min after the induction. Scale bar, 20 ms, 50 pA.
(E) LTP induced at the recurrent commissural/associational (C/A)-CA3 synapses in slices from Psen1L435F/+; Psen2/ mice and littermate controls. LTP was
induced with three trains of high-frequency stimulation (HFS). Representative traces before (thin) and after (thick) LTP induction are shown. Superimposed traces
are averages of four consecutive responses 1 min before and 50 min after HFS. The lack of response to DCG IV, which selectively inhibits mossy fiber LTP,
confirms that the responses are obtained from (C/A)-CA3 synapses. Scale bar, 10 ms, 0.5 mV.
(F) Increased synaptic depression at (C/A)-CA3 synapses during LTP-inducing stimulation in Psen1L435F/+; Psen2/ mice. Insets show representative fEPSP
traces obtained during single stimulation train. Scale bar, 10 ms, 2 mV.
The values in parentheses indicate the number of neurons or slices (left) and the number of mice (right) used in each experiment. Data are represented as mean ±
SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.in memory, synaptic function, and neuronal survival (Lee et al.,
2014; Tabuchi et al., 2009). In principle, there are two potential
explanations for these unexpected in vivo findings: the essential
roles played by PS in the maintenance of memory and synaptic
function and protection of cortical neurons from neurodegener-
ation may represent mere coincidence with no relevance to
FAD; or alternatively, pathogenic PSEN mutations compromise
the essential physiological roles of PS in memory, synaptic func-tion, and neuronal survival, leading over time to neurodegenera-
tion and dementia in FAD.
The current study was designed to address this important
unanswered question as to whether PSEN mutations indeed
compromise the essential functions of PS in the brain, particu-
larly with respect to adult brain phenotypes relevant to FAD.
We chose two independent mutations PSEN1 L435F and
C410Y, both of which were clinically and neuropathologicallyNeuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc. 975
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confirmed in multiple early-onset FAD families (Campion et al.,
1995, 1999; Goudsmit et al., 1981; Heilig et al., 2010; Poorkaj
et al., 1998; Rogaeva et al., 2001; Sherrington et al., 1995).
Each mutation was introduced into the genomic locus of the
Psen1 gene, so that the FAD mutations are expressed under
the control of the endogenous regulatory elements as in human
patients. Thus, these KImice are genetically equivalent to human
FAD patients carrying the same PSEN1 mutation.
To our great surprise, both homozygous L435F and C410Y KI/
KI mice are phenotypically indistinguishable from Psen1/mice
(Shen et al., 1997) and exhibit perinatal lethality with complete
penetrance (Figure 1, Table S1). However, in contrast to the
absence of Psen1 mRNA and protein in Psen1/ mice, levels
of Psen1 mRNA are normal in the brain of L435F and C410Y
KI/KI mice (Figure 1). Levels of PS1 NTFs and CTFs are drasti-
cally reduced in the brain of L435F and C410Y KI/KI mice with
a greater reduction by the L435F mutation (Figure 1). This minor
difference between the two mutations correlates with the
severity of the phenotypes in L435F and C410Y KI/KI newborn
pups (Figure 1) and is consistent with earlier reports regarding
the functional impairment of the presenilinase and g-secretase
activity caused by these two mutations (Heilig et al., 2010,
2013). Corresponding to these changes, PS1 holoprotein accu-
mulates in the L435F and C410Y KI/+ and KI/KI brains in a KI
allele dosage-dependent manner (Figure 1). Importantly, PS1
holoprotein appears to participate in the stable g-secretase
complex, as levels of other g-secretase components are unaf-
fected inKI/KImice but are reduced inPsen1/mice (FigureS1).
Thus, the L435F and C410Y mutations do not affect Psen1
mRNA expression, but drastically reduce presenilinase activity
and the production of the functional PS1 NTFs and CTFs.
Further analysis revealed impaired neurogenesis and reduced
neural progenitor population in L435F and C410Y KI/KI brains
(Figure 2), similar to Psen1 null embryos (Handler et al., 2000;
Shen et al., 1997). Notch signaling evaluated by the expression
of the Notch target Hes5 is reduced in L435F and C410Y KI/KI
embryonic brains (Figure 2). NICD production, measured by an
in vitro g-secretase assay, is reduced in L435F and C410Y
KI/+ brains and abolished in L435F and C410Y KI/KI brains (Fig-
ure 2), indicating that both L435F and C410Ymutations eliminate
g-secretase activity. This interpretation is further supported by
the findings that the CTFs of APP and N-cadherin, both of which
are g-secretase substrates, accumulate dramatically in L435F
and C410Y KI/KI brains to a level comparable to that of Psen1/Figure 7. The L435F Mutation Causes Age-Dependent Neurodegenera
(A) Comparison of brain morphology between Psen1F/L435F; Psen2/; Cre mice
stained comparable sagittal brain sections. Right: cortical volume and neuron num
immnostaining, respectively. Cortical volume and neuron number are normal at 2 m
age in Psen1F/L435F; Psen2/; Cre mice relative to controls (nR 3 for each geno
(B) More TUNEL-positive cells are observed in the cerebral cortex of Psen1F/L435
age. Scale bar, 0.1 mm.
(C) More active caspase-3-positive cells are detected in the cerebral cortex of Pse
of age. Scale bar, 0.1 mm.
(D) Increased GFAP immunoreactivity in the cortex of Psen1F/L435F; Psen2/; Cre
magnification views of the boxed area in the cortex. Western analysis also shows
compared to littermate control Psen1F/F; Psen2/ and Psen1F/+; Psen2/; Crem
**p < 0.01; ***p < 0.001. Scale bar, 0.1 mm.
See also Figure S6.brains (Figure 3, Figure S2) and that g-secretase-mediated pro-
duction of Ab40 and Ab42 is abolished in KI/KI brains (Figure 3).
These data demonstrate that the L435F and C410Y mutations
abolish g-secretase activity, leading to accumulation of g-secre-
tase substrates and impairment of Notch signaling and neuro-
genesis. This study demonstrates that FAD mutations in the
PSEN genes can cause complete loss of its function and g-sec-
retase activity in vivo and can recapitulate Psen1 null pheno-
types in homozygosity.
The loss of PS1 and g-secretase function brought about in vivo
by the L435F andC410Ymutations is remarkably consistent with
their previously reported effects in a sensitive cell-based system
(Heilig et al., 2010, 2013). These mutations are likely particularly
deleterious to g-secretase activity due to their predicted prox-
imity to the enzyme active site (Sato et al., 2008) and the intro-
duction of bulky aromatic side chains, which likely disrupts the
structure of g-secretase. Analysis of a panel of FAD mutations
in the same cell-based system demonstrated uniform impair-
ment of g-secretase activity, with the severity varying among
mutations (Heilig et al., 2010, 2013). Thus, we suggest that the
loss of in vivo function conferred by the L435F and C410Y muta-
tions analyzed here represents a general property of FAD muta-
tions. Our findings may differ from previously reported PSEN1 KI
(e.g., M146V) and transgenic mice due to the varying severity of
different PSEN1mutations on impairment of g-secretase activity
and due to overexpression of mutant PS1 transgene that could
compensate for the partial loss of PS1 function.
In contrast to abolished production of Ab40 and Ab42 in KI/KI
embryonic brains, their production is reduced in KI/+ embryonic
and adult brains measured by in vitro g-secretase assay (Fig-
ure 3). Steady-state levels of Ab40 and Ab42measured by ELISA
are also reduced in the KI/+ adult brain, and the reduction of
Ab40 is slightly greater than that of Ab42, leading to a modest,
but significant, increase (15%) of theAb42/Ab40 ratio (Figure 3).
Similar results (Figure 4, Table S2) were obtained when L435F
KI/+ mice were crossed to APP transgenic mice overexpressing
(2-fold) either human wild-type (I5 line) or mutant (J20 line) APP
containing both the Swedish and the Indiana mutations (Mucke
et al., 2000). Strikingly, heterozygosity for the L435F KI mutation
markedly accelerates amyloid deposition in mutant APP trans-
genic mice (Figure 4). This finding demonstrates that PSEN mu-
tations can act through a loss-of-function mechanism to elevate
the Ab42/Ab40 ratio and thereby promote amyloid deposition.
Since production of Ab40 and Ab42 measured by in vitrotion
and littermate controls at 2, 12, and 18 months of age. Left: images of Nissl-
ber obtained by stereological quantification following Nissl staining and NeuN
onths of age but significantly reduced at 12 (22%) and 18 (32%)months of
type at each age). Scale bar, 0.1 mm.
F; Psen2/; Cremice (n = 3) compared to control mice (n = 4) at 18 months of
n1F/L435F;Psen2/; Cremice (n = 3) relative to control mice (n = 4) at 18months
mice at 12 months of age indicates astrogliosis. Bottom images show higher-
increased levels of GFAP in the cortex of Psen1F/L435F; Psen2/; Cremice (KI)
ice (n = 8 for each genotype). Data are represented as mean ± SEM. *p < 0.05;
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Figure 8. A Schematic Model for FAD
Pathogenic PSEN1 mutations cause loss of PS1 function and g-secretase
activity, leading to AD-relevant functional and neuropathological changes,
including memory impairment, synaptic dysfunction, age-dependent neuro-
degeneration, gliosis, and dementia. In parallel, the loss of PS function
produced by pathogenic PSEN1 mutations also reduces Ab production and
increases the Ab42/Ab40 ratio due to the greater reduction of Ab40 production
compared to that of Ab42, thereby promoting amyloid plaque deposition.
Thus, PSENmutations produce the full spectrum of AD phenotypes through a
loss-of-function mechanism.g-secretase assay is reduced to comparable extents by the het-
erozygous L435F KI mutation (Figure 3), the greater reduction in
steady-state accumulation of Ab40 relative to Ab42 may reflect
their differential clearance.
Synaptic dysfunction is thought to be a pathogenic precursor
of frank neurodegeneration, and the hippocampus is particularly
vulnerable in AD. Relative to wild-type PS1, the L435F mutation
leads to impaired short-term synaptic plasticity and LTP in the
hippocampal Schaffer collateral pathway (Figure 6; Figure S5).
These synaptic deficits are compatible with the spatial memory
deficits observed in the hidden platform version of the water
maze, the radial arm maze, and the pattern completion tasks
(Figure 5; Figure S4). Similar synaptic and memory deficits
were also observed in Psen conditional knockout mice (Saura
et al., 2004; Zhang et al., 2009, 2010). Consistent with the pattern
completion deficits observed in the KI mice (Figure 5), LTP is also
impaired in the commissural/associational pathway in hippo-
campal area CA3, which is thought to play a crucial role in this
process (Figure 6; Figure S5). The pattern completion deficit ex-
hibited by L435F KI mice parallels the impaired behavioral
pattern completion reported in AD patients (Ally et al., 2013).
Importantly, compared to the wild-type Psen1 allele, the
L435F mutant allele is incapable of supporting normal neuronal978 Neuron 85, 967–981, March 4, 2015 ª2015 Elsevier Inc.survival and preventing neurodegeneration in the aging brain
and causes age-dependent neurodegeneration, as shown by
progressive loss of cortical neurons and increases of apoptosis
as well as astrogliosis and microgliosis (Figure 7; Figure S6).
Thus, this study provides an animal model in which a pathogenic
FADmutation causes progressive and widespread neurodegen-
eration. Our findings are consistent with prior reports indicating
that PSEN mutations could enhance apoptosis in cultured cells
(Vito et al., 1996; Wolozin et al., 1996). Interestingly, the extent
of neurodegeneration associated with the Psen1 L435Fmutation
is less severe compared to that in Psen conditional knockout
mice, raising the possibility that PS1 holoprotein may partially
support neuronal survival in the aging brain despite its essentially
complete loss of g-secretase activity. Further studies will be
needed to elucidate the underlying mechanism.
More than 80% of identified FAD mutations reside within the
PSEN genes, but the pathogenic mechanism remains unre-
solved. While earlier studies supported a toxic gain-of-function
pathogenic mechanism based on excessive production of Ab42
(Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996),
this hypothesis is at odds with several lines of experimental
data. For example, overproduction of Ab42, even at massive
levels (e.g., J20 mice overproduce Ab42 >40-fold at 2 months
and >6,400-fold at 17 months), did not produce significant neu-
rodegeneration in mouse models (Irizarry et al., 1997; Saura
et al., 2005). Human FAD patients carrying PSEN1 mutations
develop the disease at earlier ages than APP mutation carriers
(Ryman et al., 2014), even though PSEN1 mutations have
modest effects on the Ab42/Ab40 ratio in mice (e.g., 15% in-
crease for the L435F mutation while overall production of
Ab42 and Ab40 is reduced). Furthermore, FAD PSEN mutations
cause loss of PS activity in C. elegans (Levitan et al., 1996) and
in cultured cells (Heilig et al., 2010, 2013; Song et al., 1999), and
loss of PS in the adult mouse brain recapitulates widespread
age-dependent neurodegeneration, gliosis, memory loss, and
synaptic dysfunction (Beglopoulos et al., 2004; Saura et al.,
2004; Wines-Samuelson et al., 2010). These observations
suggest that the pathogenic mechanism underlying PSEN mu-
tations is more complex than initially anticipated. Our in vivo
analysis of two independent clinical PSEN1 mutations provides
important experimental support for the Presenilin hypothesis,
which posits that loss of PS function plays an important role
in the pathogenesis of FAD (Kelleher and Shen, 2010; Shen
and Kelleher, 2007).
Through the development and multidisciplinary analysis of KI
mice expressing PSEN1 mutations, the current study reveals
two parallel pathways affected by PSEN mutations that are
relevant to FAD pathogenesis (Figure 8). Pathogenic PSEN mu-
tations cause synaptic dysfunction, memory impairment, and
age-dependent neurodegeneration via a loss of essential PS
functions. In addition, loss of PS function conferred byPSENmu-
tations promotes amyloid pathology by inhibiting g-secretase
activity, decreasing Ab production, and increasing the Ab42/40
ratio due to a greater relative reduction in Ab40 accumulation
(Figure 8). An intriguing implication of our findings is that thera-
peutic strategies aimed at restoring, rather than inhibiting,
normal PS function in the brainmay hold promise for the effective
treatment of AD.
EXPERIMENTAL PROCEDURES
A brief description of the experimental procedures is included below, and full
experimental details can be found in the Supplemental Information.
Generation of Psen1 L435F and C410Y KI Mice
Targeting vectors for the generation of the L435F and C410Y KI alleles were
constructed by PCR amplification of the 50 and 30 homologous sequences
from genomic DNA followed by site-directed mutagenesis to introduce the
mutation (1303C/T in exon 12 for L435F, 1229G/A in exon 11 for C410Y).
The targeting vector was transfected into embryonic stem cells (ESCs), and
the ESCs carrying the correct homologous recombination events were
screened and confirmed by Southern analysis. The correctly targeted ESCs
were injected into blastocysts to generate chimeric mice. Mice carrying the
targeted allele were crossed with Camk2a-Cre transgenic mice (Saura et al.,
2004) to remove the floxed neomycin cassette and produce heterozygous KI
mice. L435F KI/+ mice were crossed with Psen2/ (Steiner et al., 1999) to
generate Psen1L435F/+; Psen2/ mice, which were further crossed with
Psen1F/F; Psen2/; Camk2a-Cre mice to generate Psen1F/L435F; Psen2/;
Camk2a-Cremice. Mice were maintained on the C57BL6/J-129 hybrid genetic
background, and littermate controls were used for all analysis. Electrophysio-
logical, behavioral, histological, and biochemical analyses were performed in a
genotype-blind manner. All procedures relating to animal care and treatment
conformed to institutional and NIH guidelines.
In Vitro g-Secretase Assay
g-Secretase activities were measured by cell-free in vitro assay using
CHAPSO-solubilized brain fractions and bacterially expressed recombinant
proteins as substrates (Takahashi et al., 2003). See Supplemental Information
for full experimental details.
ELISA
Ab40 and Ab42 generated in in vitro assays were measured using the
11A50-B10/4G8 and 12F4/4G8 sandwich ELISA, respectively (Watanabe
et al., 2012), and the Ab antibodies were purchased from Covance. Endog-
enous mouse and human Ab40 and Ab42 were measured by MSD 96-well
MULTI-SPOT Human/Rodent (4G8) Abeta Triplex Ultra-sensitive Assay
(MesoScale Discovery). See Supplemental Information for full experimental
details.
Behavioral Analysis
Littermate male mice were used in the behavioral tests. For the Morris water
maze tasks, mice were trained for 14 days with four trials daily, and the full-
cue probe tests were administered at days 7 and 13, and the partial-cue probe
test was administered at day 14. For the radial arm maze, all mice were single
housed and fed restrictively to reduce and maintain their body weight by 20%
before and during the 8-day training session. See Supplemental Information
for full experimental details.
Electrophysiological Analysis
Acute hippocampal slices (400 mm) were prepared and recorded as described
previously (Zhang et al., 2009). See Supplemental Information for full experi-
mental details of field and whole-cell recording at hippocampal Schaffer
collateral-CA1 synapses and recurrent commissural/associational-CA3
synapses.
Histological Analysis
Embryonic brains were dissected at E16.5 and processed for serial paraffin
sections (10 mm). Every fifth section was stained with H&E, and comparable
sections from both genotypic groups were compared. The number of Ki67-
immunoreactive cells was quantified using four comparable sections per brain
and four brains per genotype. Adult brains were perfused with PBS, fixed in
4% PFA, processed for paraffin embedding, and serially sectioned (10 mm).
Adult brain sections were stained with 0.5% cresyl violet (Nissl) or immuno-
stained with antibodies against NeuN (1:300; Millipore), cleaved caspase-3
(1:100; Cell Signaling Technology), GFAP (1:500; Sigma), Iba1 (1:250; Wako),
and Ab (R1282; 1:1,000).Statistical Analysis
Statistical analysis was performed using one-way ANOVA or two-tailed un-
paired Student’s t test for all comparisons of the biochemical, behavioral,
and electrophysiological results, except that two-way ANOVA was used to
determine the genotypic effects on latencies in the water maze, reference er-
rors and percentages of 45 turns in the radial arm maze, and EPSCs of
NMDAR. A value of p < 0.05 was considered significant. All data are repre-
sented as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2015.02.010.
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